Table 2 Comparison of active surveillance versus radical prostatectomy (A) or versus any local treatment (prostatectomy or radiotherapy) in relation to different domains of HRQoL measures.

Domain A: general health-related quality of life (HRQOL) ^a

β

95% CI

p

β

95% CI

p

 EORTC QLQ-C30: global health status

1.61

−0.60; 3.82

0.154

−0.26

−3.74; 3.22

0.882

 EORTC QLQ-C30: physical functioning

−0.47

−1.47; 0.53

0.359

−0.46

−1.24; 0.32

0.246

 EORTC QLQ-C30: role functioning

−0.68

−1.83; 0.46

0.242

−0.85

−1.96; 0.27

0.136

 EORTC QLQ-C30: emotional functioning

−0.35

−1.30; 0.60

0.469

−1.19

−2.96; 0.58

0.187

 EORTC QLQ-C30: social functioning

−0.18

−3.12; 2.75

0.903

−0.37

−2.83; 2.08

0.765

 EORTC QLQ-C30: cognitive functioning

−0.80

−2.17; 0.56

0.248

−1.51

−3.05; 0.02

0.054

 HADS: anxiety score

0.22

−0.08; 0.51

0.150

0.47

−0.16; 1.10

0.147

 HADS: depression score

0.16

−0.01; 0.33

0.051

0.36

0.13; 0.60

0.002

 PR25: sexual function

8.27

5.57; 10.96

<.001

6.30

2.58; 10.03

0.001

 PR25: sexual activity

6.70

4.19; 9.20

<.001

5.61

3.38; 7.84

<0.001

 IIEF: erectile function

3.74

1.99; 5.49

<.001

2.53

0.34; 4.71

0.023

Domain D: urinary/prostatic symptoms and bowel function^b

OR

95%CI

p

OR

95% CI

p

 PR25-Use of incontinence aids

0.14

0.09; 0.23

<.001

0.21

0,13; 0,33

<0.001

 IPSS-presence of moderate/severe prostatic symptoms

2.77

1.52; 5.06

0.001

2.15

1.29; 3.59

0.003

 PR25-presence of bowel symptoms

1.24

0.72; 2.12

0.439

0.97

0.57; 1.69

0.960